Singapore markets open in 7 hours 30 minutes

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
42.52+0.07 (+0.16%)
As of 01:29PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 7.73B
Enterprise value 7.26B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)13.70
Enterprise value/revenue N/A
Enterprise value/EBITDA -12.80

Trading information

Stock price history

Beta (5Y monthly) 1.41
52-week change 345.83%
S&P500 52-week change 324.13%
52-week high 343.59
52-week low 319.59
50-day moving average 341.27
200-day moving average 337.46

Share statistics

Avg vol (3-month) 31.57M
Avg vol (10-day) 31.84M
Shares outstanding 5182.2M
Implied shares outstanding 6182.2M
Float 877.82M
% held by insiders 115.32%
% held by institutions 185.36%
Shares short (28 Jun 2024) 46.59M
Short ratio (28 Jun 2024) 43.11
Short % of float (28 Jun 2024) 47.58%
Short % of shares outstanding (28 Jun 2024) 43.62%
Shares short (prior month 31 May 2024) 47.3M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-29.79%
Return on equity (ttm)-92.45%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -484.52M
Net income avi to common (ttm)-460.47M
Diluted EPS (ttm)-2.73
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)846.29M
Total cash per share (mrq)4.64
Total debt (mrq)482.3M
Total debt/equity (mrq)85.44%
Current ratio (mrq)10.22
Book value per share (mrq)3.10

Cash flow statement

Operating cash flow (ttm)-367.05M
Levered free cash flow (ttm)-212.07M